湖北济川药业股份有限公司关于曹飞先生要约收购公司股份交割完成的公告

Core Points - The announcement details the completion of the share acquisition by Mr. Cao Fei, who made a comprehensive offer to acquire all unrestricted circulating shares from shareholders other than certain specified parties [1][2] - The total number of shares offered for acquisition was 350,841,357, representing 38.06% of the company's total share capital, with an adjusted offer price of 24.85 yuan per share [1] - The acquisition period was set from June 18, 2025, to July 17, 2025 [1] Summary of Acquisition Results - By the end of the acquisition period on July 17, 2025, a total of 34 shareholder accounts accepted the offer, amounting to 16,300 shares, which is only 0.0018% of the total share capital [2] - Following the completion of the acquisition, Mr. Cao Fei directly holds 16,300 shares and indirectly controls 416,757,360 shares through his controlled entity, Jichuan Holdings, and 100,000,000 shares through another entity, Tibet Jichuan [2] - In total, Mr. Cao Fei directly and indirectly controls 516,773,660 shares, which is 56.07% of the company's total share capital, while he and his concerted actor, Mr. Cao Longxiang, collectively control 563,612,118 shares, accounting for 61.15% of the total share capital [2]